.png){kind=icon}
.png){kind=icon}
Return
Health-related quality of life with pertuzumab retreatment: Secondary analysis of the PRECIOUS trial
.png){kind=icon}
OA
AI
N
Y
I
S
T
Y
T
T
T
K
T
T
F
T
N
S
M
DOI：10.1016/j.breast.2026.104790.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Background: Retreatment with pertuzumab has demonstrated survival benefit in previously treated human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer, but its effect on health-related quality of life (HRQoL) is not well established. Methods: This secondary analysis of the randomized, open-label phase III PRECIOUS trial evaluated HRQoL in women previously treated with pertuzumab, trastuzumab, and chemotherapy. Patients were randomized 1:1 to pertuzumab plus trastuzumab plus chemotherapy (PTC) or trastuzumab plus chemotherapy (TC). HRQoL was assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B). The primary endpoint was timeto-deterioration (TTD) in the Breast-Trial Outcome Index (B-TOI), defined as a >= 5-point decline. Secondary endpoints included TTD in the FACT-B total score, General Subscale, and Breast Cancer Subscale. Longitudinal changes were analyzed using linear mixed-effects models. Results: Of 217 eligible patients, 178 were included in the HRQoL analysis (median age: 57 years in PTC and 60 years in TC). No significant between-group differences in TTD for B-TOI were observed (hazard ratio, 1.22; 95% CI, 0.86-1.90; p = 0.23). Secondary TTD endpoints also showed no differences. Mixed-effects models indicated that TC had better B-TOI and Breast Cancer Subscale scores at week 6, but these early differences were not sustained beyond week 12. Conclusion: Pertuzumab retreatment was not associated with clinically meaningful deterioration in HRQoL. These findings support the use of dual HER2 blockade beyond progression in appropriately selected patients.
Keywords:
HER2-Positive breast cancer
Pertuzumab retreatment
Health-related quality of life
Functional assessment of cancer therapy-breast (FACT-B)
Time-to-deterioration
Metastatic breast cancer
Dual HER2 blockade
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
7.9
Papers:
7.2K
Citations:
8.2K
Organization
Cited Papers